Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data
During active weight loss the International Society of Sports Nutrition recommends up to 2.2 grams per kilogram for maximum lean mass retention
Ready to see if GHK-Cu is right for you
One well-known issue is erectile dysfunction (ED), where it's tough to get or keep an erection long enough for sex
If your COMT gene has been dirty for a while, you may experience associated health conditions
